drugset

drugset / Trial / NCT01149200

Proof-of-Principle Study of TC-6499 in the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS)

NCT01149200 ↗

Phase 2 Completed 24 enrolled Targacept Inc.

RandomizedParallel-groupDouble-blindTreatment

Summary

Study is to assess the effectiveness of TC-6499 in the treatment of constipation predominant IBS patients over a 28-day period.

Timeline

Start: 2010-05
Primary completion: 2010-10
Completion: 2010-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	simpinicline	Small molecule	5 mg	Oral

Indications